COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single-Dose of PF-06651600 in Healthy Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03821493
Recruitment Status : Completed
First Posted : January 29, 2019
Last Update Posted : June 28, 2019
Information provided by (Responsible Party):

Brief Summary:

This study will estimate the impact of a strong CYP3A4 inhibitor (itraconazole) on the pharmacokinetics of an investigational product (PF-06651600) in healthy adult participants.

This is an open-label, fixed sequence two period study with healthy participants that will receive a single dose of PF-06651600 alone and co-administered with multiple doses of itraconazole at a single center.

Participants will be screened within 28 days of the first dose of the investigational products and if entry criteria are met, the participant will report to the clinic on the day before the Day 1 visit. On Day 1 of Period 1, each participant will receive a 30 mg dose of PF-06651600 and PK samples will be collected for 48 hours. In Period 2, participants will receive itraconazole solution from Day 1-5. On Day 4 of Period 2 the participant will receive 30 mg of PF-06651600 with the itraconazole. PK samples will be collected up to 48 hours after the PF-06651600 dose. Participants will be confined for a total of 9 days in the clinic. The participant will be followed up by phone contact.

Condition or disease Intervention/treatment Phase
Healthy Participants Drug: PF-06651600 10 mg tablets Drug: Itraconazole Solution 200 mg Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Actual Study Start Date : February 21, 2019
Actual Primary Completion Date : April 6, 2019
Actual Study Completion Date : June 4, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: PF-06651600 treatment arm
This arm includes two treatment periods. Period 1-Single oral dose of PF-06651600 30 mg as tablets on Day 1 followed by Period 2 in which itraconazole 200 mg (oral solution) is given for 5 days. On Day 4 of Period 2, a single oral dose of PF-06651600 30 mg is given with itraconazole
Drug: PF-06651600 10 mg tablets

On Day 1 in Period 1, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered.

On Day 4 of Period 2, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered after itraconazole.

Drug: Itraconazole Solution 200 mg

Itraconazole 200 mg will be administered as 20 mL (10 mg/mL) oral solution once daily on Days 1-5 in Period 2.

On Day 4 of Period 2, co-administration of itraconazole 200 mg and PF-06651600 30 mg will occur. Itraconazole will be administered first followed by PF-06651600 tablets.

Other Name: Sporanox Oral Solution

Primary Outcome Measures :
  1. Single dose Area under the curve from time zero to infinity [AUC (0-inf)] of PF-06651600 [ Time Frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 and 48 hours ]
    Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinity.

  2. Maximum observed plasma concentration of PF-06651600 [ Time Frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 and 48 hours ]
    Peak concentration of PF-06651600

Secondary Outcome Measures :
  1. Incidence of treatment-emergent adverse events (AEs) [ Time Frame: Baseline up to 35 days ]
  2. Number of adverse events leading to discontinuation [ Time Frame: Baseline up to 35 days ]
  3. Number of participants with clinically significant change in vital signs from Baseline [ Time Frame: Baseline to Day 9 ]
  4. Number of participants with clinically significant abnormalities in clinical laboratory values [ Time Frame: Baseline to Day 9 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations and other study procedures.
  • Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg.

Exclusion Criteria:

  • Evidence of congestive heart failure or history of congestive heart failure or any of the following: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident including transient ischemic attack or pulmonary embolus.
  • Known hypersensitivity to itraconazole or it excipients or to other azole antifungals.
  • Infection with Hepatitis B, C or HIV
  • Known present or history of malignancy other than a successfully treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03821493

Layout table for location information
Pfizer Clinical Research Unit
Brussels, Be-bru, Belgium, B-1070
Sponsors and Collaborators
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer Identifier: NCT03821493    
Other Study ID Numbers: B7981023
2018-004664-55 ( EudraCT Number )
First Posted: January 29, 2019    Key Record Dates
Last Update Posted: June 28, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at:

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pfizer:
Drug-Drug Interaction
Additional relevant MeSH terms:
Layout table for MeSH terms
Pharmaceutical Solutions
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors